Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Anti-RANKL Monoclonal Antibody by Jiangsu Pacific Meinuoke Bio-Pharmarceutical for Osteoporosis: Likelihood of Approval
Anti-RANKL Monoclonal Antibody is under clinical development by Jiangsu Pacific Meinuoke Bio-Pharmarceutical and currently in Phase I for Osteoporosis. According...